Clinical trial · no report yet · Phase 3

EVOLVE 1

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

NCT07075016 ↗
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
YouTube	2
X threads	2
Podcasts	1

The trial

ClinicalTrials.gov

Official title: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Phase: Phase 3
Status: Recruiting
Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax 400; Placebo
Arms: Placebo comparator: Venetoclax-placebo · Placebo comparator
Experimental: Venetoclax · Experimental
Enrollment: 227 (estimated)
Primary outcomes: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland with German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network, Gruppo Italiano Malattie EMatologiche dell'Adulto, Swiss Group for Clinical Cancer Research (SAKK), Danish Acute Leukemia Group, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, Nordic AML Group
Start: Aug 5, 2025
Primary completion: Dec 2028 (estimated)
Results posted: No
Registry record: NCT07075016 · updated Aug 19, 2025